Details for Patent: 6,432,948

Summary for Patent: 6,432,948

Title:	USE OF 7-(2-OXA-5,8-DIAZABICYLCO[4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HELIOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES
Abstract:	The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives, which are substituted in the 7-position by a 2-oxa-5,8-diazabicyclo[4.3.0]-non-8-yl) radical, and their pharmaceutically utilizable hydrates and/or salts for the therapy of Helicobacter pylori infections and the gastroduodenal disorders associated therewith.
Inventor(s):	Matzke; Michael (Wuppertal, DE), Petersen; Uwe (Leverkusen, DE), Jaetsch; Thomas (Koln, DE), Bartel; Stephan (Kurten, DE), Schenke; Thomas (Gladbach, DE), Himmler; Thomas (Odenthal-Globusch, DE), Baasner; Bernd (Gladbach, DE), Werling; Hans-Otto (Wuppertal, DE), Schaller; Klaus (Wuppertal, DE), Labischinski; Harald (Wuppertal, DE)
Assignee:	Bayer Aktiengesellschaft (Leverkusan, DE)
Application Number:	09/436,316
Patent Claim Types: see list of patent claims	Use; Compound; Composition;

Drugs Protected by US Patent 6,432,948

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 6,432,948

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	196 52 239	Dec 16, 1996

International Family Members for US Patent 6,432,948

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	214929
Australia	5854198
Australia	717751
Bulgaria	103474
Bulgaria	64615